NasdaqGS:IONSBiotechs
Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Stock (IONS)
Novartis reported that pelacarsen, co developed with Ionis Pharmaceuticals to lower lipoprotein(a), reduced Lp(a) levels in a large Phase 3 trial but did not cut heart attacks, strokes, or related cardiovascular events. This raises questions about how Lp(a) lowering translates into clinical benefit.
The pelacarsen setback removes a potential cardiovascular revenue pillar for Ionis Pharmaceuticals and places more pressure on its remaining late stage RNA medicines to support the commercial...